Clinical trial
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
NCT05294328 is registered in ClinicalTrials.gov with LENZ Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
- Lead sponsor
- LENZ Therapeutics, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 5, 2022
- Completion date
- September 10, 2022
- Enrollment
- 68 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.